Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO ...

Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial for those ...

Roche has demonstrated the power of combining two of oncology's hottest modalities—bispecifics and antibody-drug conjugates ...

Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma – Pivotal Phase III SUNMO study demonstrated an 11.5 ...

Polivy is a prescription drug used to treat B cell lymphoma. Learn about the common, mild, and serious side effects it can cause and how to manage them.

Swiss pharma giant Roche has released encouraging results from the Phase III SUNMO study showing Lunsumio (mosunetuzumab) administered subcutaneously in combination with Polivy (polatuzumab vedotin), ...

Polivy is a prescription medicine used with other medicines (a rituximab product, cyclophosphamide, doxorubicin, and prednisone) as a first treatment for adults who have moderate to high risk ...

Results from the SUNMO study will be submitted to global health authorities, including the US Food and Drug Administration. The National Comprehensive Cancer Network® (NCCN®) has recently added ...

Polivy binds to cancer cells such as those expressing CD79b and destroys these B cells through the delivery of an anti-cancer agent, which is thought to minimise the effects on normal cells. Polivy is ...

SOUTH SAN FRANCISCO, Calif., June 20, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO [NCT05171647] study showing Lunsumio® ...

Polivy binds to cancer cells such as those expressing CD79b and destroys these B cells through the delivery of an anti-cancer agent, which is thought to minimise the effects on normal cells.